Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study explores immunotherapy for rare cancers in japanese patients

NCT ID NCT07302347

Recruiting now Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times

Summary

This study is testing the drug pembrolizumab in Japanese children with solid tumors or lymphomas, and in Japanese adults with advanced Merkel cell skin cancer. The main goals are to check the drug's safety, how the body processes it, and whether tumors shrink. About 20 participants will receive the treatment to gather this information.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, MERKEL CELL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer classic Hodgkin lymphoma cutaneous melanoma cutaneous neuroendocrine carcinoma lymphoma neoplasm primary mediastinal large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, MERKEL CELL LYMPHOMA MALIGNANT NEOPLASM

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Hyogo Prefectural Kobe Children's Hospital ( Site 0006)

    RECRUITING

    Kobe, Hyōgo, 650-0047, Japan

  • Nagoya City University Hospital ( Site 0003)

    RECRUITING

    Nagoya, Aichi-ken, 467-8602, Japan

  • Nagoya City University Hospital ( Site 0007)

    RECRUITING

    Nagoya, Aichi-ken, 467-8602, Japan

  • National Cancer Center Hospital ( Site 0002)

    RECRUITING

    Chūō, Tokyo, 104-0045, Japan

  • National Hospital Organization Kyushu Cancer Center ( Site 0001)

    RECRUITING

    Fukuoka, 811-1395, Japan

  • Sapporo Hokuyu Hospital ( Site 0005)

    RECRUITING

    Sapporo, Hokkaido, 003-0006, Japan

  • University Hospital,Kyoto Prefectural University of Medicine ( Site 0004)

    RECRUITING

    Kyoto, 602-8566, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.